These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7658066)

  • 1. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity.
    Tang YW; Graham BS
    J Infect Dis; 1995 Sep; 172(3):734-8. PubMed ID: 7658066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine pattern is solely influenced by priming vaccine but immunity and disease by both priming and boosting vaccines in mice challenged with respiratory syncytial virus.
    Tang YW
    Virus Res; 2004 Jan; 99(1):81-7. PubMed ID: 14687950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Jung YJ; Lee Y; Lee JS; Lee YN; Park S; Kang SM
    PLoS One; 2015; 10(10):e0139916. PubMed ID: 26468884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.
    Graham BS; Henderson GS; Tang YW; Lu X; Neuzil KM; Colley DG
    J Immunol; 1993 Aug; 151(4):2032-40. PubMed ID: 8345194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.
    Tang YW; Graham BS
    J Clin Invest; 1994 Nov; 94(5):1953-8. PubMed ID: 7962541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern.
    Waris ME; Tsou C; Erdman DD; Zaki SR; Anderson LJ
    J Virol; 1996 May; 70(5):2852-60. PubMed ID: 8627759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.
    Hsu SC; Chargelegue D; Obeid OE; Steward MW
    J Gen Virol; 1999 Jun; 80 ( Pt 6)():1401-1405. PubMed ID: 10374957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.
    Lee YT; Ko EJ; Kim KH; Hwang HS; Lee Y; Kwon YM; Kim MC; Lee YN; Jung YJ; Kang SM
    J Biomed Nanotechnol; 2017 Jan; 13(1):84-98. PubMed ID: 29302248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity.
    Ostler T; Ehl S
    Eur J Immunol; 2002 Sep; 32(9):2562-9. PubMed ID: 12207340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.
    Tripp RA; Anderson LJ
    J Virol; 1998 Nov; 72(11):8971-5. PubMed ID: 9765442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Moore EG
    Viral Immunol; 2007; 20(2):261-75. PubMed ID: 17603843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.
    Zhang L; Li H; Hai Y; Yin W; Li W; Zheng B; Du X; Li N; Zhang Z; Deng Y; Zeng R; Wei L
    J Virol; 2017 May; 91(10):. PubMed ID: 28275186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.
    Aung S; Tang YW; Graham BS
    J Virol; 1999 Nov; 73(11):8944-9. PubMed ID: 10515999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.